About us Pricing ContactSubscribe

reviewTop 1% cited

FDA-approved small-molecule kinase inhibitors

Trends in Pharmacological Sciences · 2015 · Vol. 36(7) · pp. 422–439

Peng Wu✉(Technical University of Denmark)Thomas E. Nielsen(Novo Nordisk (Denmark))Mads H. Clausen(Technical University of Denmark)

View via DOI Publisher page

Chronic Lymphocytic Leukemia Research Advanced Breast Cancer Therapies Melanoma and MAPK PathwaysPharmacologyMedicine

MeSH terms

Phosphoinositide-3 Kinase InhibitorsEnzyme InhibitorsModels, MolecularPhosphotransferasesProtein BindingProtein-Tyrosine KinasesUnited StatesUnited States Food and Drug AdministrationMolecular StructureDrug ApprovalProtein Serine-Threonine KinasesPhosphatidylinositol 3-KinasesReceptor Protein-Tyrosine KinasesProtein Kinase Inhibitors

Funding

Bristol-Myers Squibb
Lundbeckfonden
Eisai
Pharmacyclics

Citations

991

FWCI

57.78

field-weighted impact

References

115

Percentile

100%

vs. same field & year

Citations per year

Cited by

Signal Transducer and Activator of Transcription (STATs) Proteins in Cancer and Inflammation: Functions and Therapeutic Implication

Frontiers in Oncology · 2019 · 340 citations

Targeting Free Radicals in Oxidative Stress-Related Human Diseases

Trends in Pharmacological Sciences · 2017 · 1,086 citations

References

JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis

Leukemia · 2004 · 685 citations

ERBB receptors and cancer: the complexity of targeted inhibitors

Nature reviews. Cancer · 2005 · 3,292 citations

The biology of VEGF and its receptors

Nature Medicine · 2003 · 9,519 citations

The origins of protein phosphorylation

Nature Cell Biology · 2002 · 1,120 citations

The Protein Kinase Complement of the Human Genome

Science · 2002 · 8,071 citations

PI3K and cancer: lessons, challenges and opportunities

Nature Reviews Drug Discovery · 2014 · 1,716 citations

Comprehensive analysis of kinase inhibitor selectivity

Nature Biotechnology · 2011 · 2,330 citations

Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)

Journal of Medicinal Chemistry · 2011 · 909 citations

Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.